Schrodinger Inc
Change company Symbol lookup
Select an option...
SDGR Schrodinger Inc
DK Delek US Holdings Inc
TGLVY Top Glove Corporation Bhd
ACQRU Independence Holdings Corp
KEGS 1812 Brewing Company Inc
PHUN Phunware Inc
WFC Wells Fargo & Co
XRX Xerox Holdings Corp
BIDU Baidu Inc
CDRO Codere Online Luxembourg SA
Go

Health Care : Health Care Technology | Small Cap Blend
Company profile

Schrodinger, Inc. has developed a physics-based software platform, which enables discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories around the world. The Company also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The Company operates through two segments: software and drug discovery. The software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on building a portfolio of preclinical and clinical programs, internally and through collaborations, which has advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs include MALT1, CDC7, Wee1, and SOS1/KRAS.

Price
Delayed
$17.37
Day's Change
-0.26 (-1.47%)
Bid
--
Ask
--
B/A Size
--
Day's High
17.55
Day's Low
16.72
Volume
(Heavy Day)

Today's volume of 376,665 shares is on pace to be much greater than SDGR's 10-day average volume of 507,132 shares.

376,665

Company Profile

Schrodinger, Inc. has developed a physics-based software platform, which enables discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories around the world. The Company also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The Company operates through two segments: software and drug discovery. The software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on building a portfolio of preclinical and clinical programs, internally and through collaborations, which has advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs include MALT1, CDC7, Wee1, and SOS1/KRAS.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
7.38x
Price/Book (MRQ)
2.71x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
3.6M
Previous Month
4.1M
Percent of Float
6.19%
Days to Cover
4.8199 Days

Share Information

SDGR is in a share class of common stock
Float
58.1M
Shares Outstanding
71.2M
Institutions Holding Shares
278
77.07%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in millions.

Company Officers

  • Michael Lynton
  • Ramy FaridPres.
  • Geoffrey PorgesCFO
  • Karen AkinsanyaCorp.Exec.
  • Kenneth Patrick LortonExec.VP

Address

Insider Trading

During the most recent quarter, 5K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.